Related Experiment Video
Updated: Nov 25, 2025
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Published on: January 31, 2018
Current Advances in Burkholderia Vaccines Development
Guanbo Wang1, Paulina Zarodkiewicz1, Miguel A Valvano1
1Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
Abstract:
The genus Burkholderia includes a wide range of Gram-negative bacterial species some of which are pathogenic to humans and other vertebrates. The most pathogenic species are Burkholderia mallei, Burkholderia pseudomallei, and the members of the Burkholderia cepacia complex (Bcc). B. mallei and B. pseudomallei, the cause of glanders and melioidosis, respectively, are considered potential bioweapons. The Bcc comprises a subset of Burkholderia species associated with respiratory infections in people with chronic granulomatous disease and cystic fibrosis. Antimicrobial treatment of Burkholderia infections is difficult due to the intrinsic multidrug antibiotic resistance of these bacteria; prophylactic vaccines provide an attractive alternative to counteract these infections. Although commercial vaccines against Burkholderia infections are still unavailable, substantial progress has been made over recent years in the development of vaccines against B. pseudomallei and B. mallei. This review critically discusses the current advances in vaccine development against B. mallei, B. pseudomallei, and the Bcc.
Insights
Developing vaccines against pathogenic Burkholderia bacteria, including Burkholderia mallei, Burkholderia pseudomallei, and the Burkholderia cepacia complex, is crucial due to their antibiotic resistance and potential bioweapon status.
Area of Science:
- Microbiology
- Immunology
- Bacterial Pathogenesis
Background:
- The genus Burkholderia encompasses Gram-negative bacteria, with notable species like Burkholderia mallei, Burkholderia pseudomallei, and the Burkholderia cepacia complex (Bcc) posing significant health risks.
- Burkholderia mallei causes glanders, and Burkholderia pseudomallei causes melioidosis; both are potential bioweapons.
- The Bcc is linked to severe respiratory infections in individuals with cystic fibrosis and chronic granulomatous disease.
Purpose of the Study:
- To review and critically assess recent advancements in vaccine development targeting Burkholderia infections.
- To highlight the challenges and progress in creating effective prophylactic vaccines against B. mallei, B. pseudomallei, and Bcc.
Main Methods:
- Literature review of current research on Burkholderia vaccine development.
- Analysis of vaccine strategies targeting key pathogenic Burkholderia species.
Main Results:
- Significant progress has been made in developing vaccines against B. pseudomallei and B. mallei.
- Challenges remain in vaccine development due to the intrinsic multidrug resistance of Burkholderia species.
Conclusions:
- Vaccines represent a promising alternative to antibiotics for combating difficult-to-treat Burkholderia infections.
- Continued research and development are essential for creating viable commercial vaccines against these pathogens.
